Introduction: Interleukin-17 (IL-17) is a proinflammatory cytokine considered to play a significant role in the immunopathogenesis of plaque psoriasis. As a result, focus in clinical trials has undergone a shift towards disease specific targets, with the goals of more effective treatment and ...
Chiricozzi, A., & Krueger, J. G. (2013). IL-17 targeted therapies for psoriasis. Expert Opinion on Investigational Drugs, 22(8), 993Y1005.Chiricozzi A, Krueger JG. IL-17 targeted therapies for psoriasis. Expert Opin Investig Drugs 2013 ; 22:993 - 1005; http://dx.doi.org/ 10.1517...
Psoriasis is a chronic, immune-mediated, inflammatory disease that is pathogenically driven by proinflammatory cytokines. This article reviews the immunologic role of interleukin (IL)-17, the major effector cytokine in the pathogenesis of psoriatic disease, along with the rationale for targeting the ...
The newest biologic agents approved by the FDA for the treatment of psoriasis are targeted IL-17 pathway inhibitors, three of which have completed phase III clinical trials. Secukinumab, a fully human monoclonal antibody, and ixekizumab, a humanized monoclonal antibody, act by directly binding and ...
银屑病患者使用IL-17和IL-23抑制剂后具有较高的药物生存期,其中古塞奇尤单抗和瑞莎珠单抗的药物生存期最高。 参考文献: Thomas SE, Barenbrug L, Hannink G, Seyger MMB, de Jong EMGJ, van den Reek JMPA. Drug Survival...
OliveLeavy. (2012) Immunotherapy: Therapeutic targeting of IL-17 for psoriasis. Nature Reviews Immunology 12 , 322-322 /Olive Leavy. (2012) Immunotherapy: Therapeutic targeting of IL-17 for psoriasis. Nature Reviews Immunology 12 , 322-322 /...
Data from two Phase II double-blind, placebo-controlled clinical trials suggest that inhibition of interleukin-17 (IL-17) may be an effective and targeted therapy for psoriasis. The IL-17 receptor-specific antibody brodalumab (AMG 827; Amgen) and the IL-17A-specific monoclonal antibody ixekizumab...
A.; Antonelli, F.; Coscarella, G.; Rubegni, P.; Peris, K. IL-17 Inhibition: A Valid Therapeutic Strategy in the Management of Hidradenitis Suppurativa. Pharmaceutics 2023, 15, 2450.J M Fletcher, B Moran, A Petrasca, C M Smith, IL-17 in inflammatory skin diseases psoriasis and hidra...
IL-17A . IL-17F . IL-17 receptor A . Innate immunity . Adaptive immunity Introduction Psoriasis is a chronic, immune-mediated, inflammatory dis- ease in which genetic and epigenetic changes result in a dis- ease phenotype characterized by altered immune function, keratinocyte activation and ...
J M Fletcher, B Moran, A Petrasca, C M Smith, IL-17 in inflammatory skin diseases psoriasis and hidradenitis suppurativa, Clinical and Experimental Immunology, Volume 201, Issue 2, August 2020, Pages 121–134. Sabat R, Jemec GBE, Matusiak Ł, Kimball AB, Prens E, Wolk K. Hidradenitis...